Walter Urba
Emeritus Member · Providence Health & Services - Oregon
Credentials: · · ·
History
Research
Improved survival with ipilimumab in patients with metastatic melanoma
New England Journal of Medicine · 2010 · Last of 29 authors · 12,191 citations
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Cell · 2017 · 1,867 citations
Journal of Clinical Oncology · 2005 · 628 citations
- DL
67 papers
39 papers
- RS
32 papers · 3 as a fellow
21 papers
- WS
18 papers
- JJ
17 papers
- JS
14 papers
- SC
14 papers
Grants
- 2008–2011
Clinical Trial of DRibble Vaccine in NSCLC
National Cancer Institute · R21
Contact PI · $653.9K · Providence Portland Medical Center
- 2004–2007
Peptide Booster Vaccination in A2+ Melanoma Patients
National Cancer Institute · R21
Contact PI · $583.4K · Providence Portland Medical Center
- 2003–2006
gp100 Peptide Immunization After Lymphocyte Depletion
National Cancer Institute · R21
Contact PI · $633.2K · Providence Portland Medical Center
- 1999–2001
Immune Response to the Mutated gp?00 Peptide (209o-2m)
National Cancer Institute · R21
Contact PI · $275.4K · Providence Portland Medical Center
Clinical trials
- 2016–2018
Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma
Principal investigator · Completed · Phase 1
BrightPath Biotherapeutics
- 2010–2026
Principal investigator · Unknown · Phase 1
Tactical Therapeutics, Inc.
- 2009–2012
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 1
Providence Health & Services
- 2007–2009
Long-term Data Collection for Subjects in MDX-010 Studies
Principal investigator · Completed
Bristol-Myers Squibb